Friday 6 November 2026 Export SYRE’s income statement to Excel — free account

Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.

EPS: −624.8%
Free cash flow: −108.8%

Quarter to September 2026, against a year earlier

104.18 7.59 +7.86%

Follow SYRE

Alert me

Market cap: $9.2B
P/E: 0.0×
Fwd P/E: −4.8×
Dividend yield: —
F-score: 3/9
Altman Z: −3.82
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Spyre Therapeutics, Inc. 10-Q filed Aug 4, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed Aug 4, 2026 · accepted 4:02 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 5, 2025: 33 added · 20 removed · 42 modified; 5 with only figures updated

Spyre Therapeutics, Inc. 10-Q filed Aug 4, 2026

What changed

Stockrow Weekly